Please assess the completion status of the following clinical trial:

Trial Title: Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 5-75 years~* Lesions must measure at least 1 cm and be primarily ulcerative~* Have cutaneous leishmaniasis proven parasitologically in the lesion selected for study~* Must have given written informed consent to participate in the study~Exclusion Criteria:~* Known drug intolerance to aminoglycosides in the patient or immediate family~* Previous use of antileishmanial drugs (within 3 months) or present use of routinely nephrotoxic or ototoxic drugs~* Patients with tuberculosis under treatment~* Potential for follow-up: have less than 7 months time remaining in present address and/or plan to leave the area for more than 30 days~* Extent of disease: more than 5 lesions or lesion equal to or greater than 5 cm or a lesion less than 5 cm from the eye, or a lesion in the face that, in the opinion of the attending dermatologist could potentially cause significant disfigurement~* Location of disease: mucosal involvement~* Disseminated disease: clinically significant lymphadenitis with nodules that are painful and greater than 1 cm in size in the lymphatic drainage of the ulcer~* Concomitant medical problems: significant medical problems of the kidney or liver as determined by history and by the following laboratory studies:~* Hearing abnormality~* Ongoing pregnancy or have plans to become pregnant~* Females of child bearing age (Tunisia Only)~* Signs or symptoms of peripheral neuropathy~Kidney: clinically significant abnormalities of urine analysis, serum levels of creatinine, BUN, total proteins greater than the upper limit of normal for the laboratory.~Liver: AST or ALT greater than the upper limit of normal for the laboratory General: glucose, Na+, or K+ greater than the upper limit of normal for the laboratory

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- WR 279,396 (Type: EXPERIMENTAL): WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin
- Placebo (Type: PLACEBO_COMPARATOR): Topical cream vehicle containing all of the components in WR 279,396 except the active ingredients.

Based on this trial design, predict the completion outcome and termination type (if applicable).